Akorn, Inc. announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8mg/2mg strengths. This launch follows an October 15, 2015 Food and Drug Administration (FDA) approval for the product. Additionally, Akorn recently launched Tobramycin Injection, USP 40 mg/mL in 2 mL and 30 mL multi-dose vials.

This launch follows a September 2014 approval for the product.